T. Klopsch

826 total citations
12 papers, 597 citations indexed

About

T. Klopsch is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, T. Klopsch has authored 12 papers receiving a total of 597 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Rheumatology, 5 papers in Immunology and 3 papers in Hematology. Recurrent topics in T. Klopsch's work include Rheumatoid Arthritis Research and Therapies (9 papers), Biosimilars and Bioanalytical Methods (3 papers) and Autoimmune and Inflammatory Disorders Research (3 papers). T. Klopsch is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (9 papers), Biosimilars and Bioanalytical Methods (3 papers) and Autoimmune and Inflammatory Disorders Research (3 papers). T. Klopsch collaborates with scholars based in Germany, Estonia and United States. T. Klopsch's co-authors include Joachim Listing, Anja Strangfeld, A. Zink, Matthias Schneider, Maria Eveslage, A Kapelle, Rolf Rau, Jörn Kekow, Erika Gromnica‐Ihle and Gerd‐Rüdiger Burmester and has published in prestigious journals such as Annals of the Rheumatic Diseases, Arthritis Research & Therapy and Rheumatology and Therapy.

In The Last Decade

T. Klopsch

12 papers receiving 576 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
T. Klopsch Germany	6	444	180	163	98	59	12	597
Ani John United States	14	416 0.9×	166 0.9×	107 0.7×	103 1.1×	70 1.2×	30	575
Kumi Shidara Japan	16	430 1.0×	126 0.7×	86 0.5×	99 1.0×	113 1.9×	30	586
Jo Ledingham United Kingdom	9	307 0.7×	114 0.6×	91 0.6×	51 0.5×	53 0.9×	13	500
Judith Sautner Austria	13	307 0.7×	100 0.6×	85 0.5×	38 0.4×	61 1.0×	39	494
Gülşen Özen Türkiye	13	372 0.8×	86 0.5×	98 0.6×	65 0.7×	81 1.4×	31	590
K. Gadsby United Kingdom	11	348 0.8×	115 0.6×	134 0.8×	67 0.7×	67 1.1×	19	565
Marco Fornaro Italy	13	224 0.5×	90 0.5×	135 0.8×	28 0.3×	45 0.8×	56	481
G S Alarcón United States	12	394 0.9×	122 0.7×	93 0.6×	50 0.5×	93 1.6×	23	585
Anabela Cardoso United States	8	268 0.6×	117 0.7×	67 0.4×	63 0.6×	46 0.8×	18	481
J.-F. Besancenot France	13	294 0.7×	43 0.2×	93 0.6×	62 0.6×	50 0.8×	47	542

Countries citing papers authored by T. Klopsch

Since Specialization

Citations

This map shows the geographic impact of T. Klopsch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Klopsch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Klopsch more than expected).

Fields of papers citing papers by T. Klopsch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. Klopsch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Klopsch. The network helps show where T. Klopsch may publish in the future.

Co-authorship network of co-authors of T. Klopsch

This figure shows the co-authorship network connecting the top 25 collaborators of T. Klopsch. A scholar is included among the top collaborators of T. Klopsch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. Klopsch. T. Klopsch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Feist, Eugen, Xenofon Baraliakos, Frank Behrens, et al.. (2022). Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes. Rheumatology and Therapy. 9(2). 621–635. 12 indexed citations

Wassenberg, Siegfried, Rolf Rau, T. Klopsch, et al.. (2022). Etanercept is Effective and Halts Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis: Final Results from a German Non-interventional Study (PRERA). Rheumatology and Therapy. 10(1). 117–133. 3 indexed citations

Gaubitz, M., et al.. (2019). Etanercept in der klinischen Routinebehandlung von Patienten mit rheumatoider Arthritis. Zeitschrift für Rheumatologie. 78(6). 552–558. 1 indexed citations

Behrens, Frank, Matthias Englbrecht, Gerd R Burmester, et al.. (2018). SAT0182 Tocilizumab s.c. – improvement of the depressiveness, fatigue and pain in ra therapy. Annals of the Rheumatic Diseases. 77. 952–952. 5 indexed citations

Richter, Adrian, Joachim Listing, M Schneider, et al.. (2015). Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. 75(9). 1667–1673. 68 indexed citations

Richter, Adrian, Anja Strangfeld, Matthias Schneider, et al.. (2015). OP0161 Discontinuation of Biologic Dmards Increases the Risk of Sepsis and Mortality After Serious Infection. Annals of the Rheumatic Diseases. 74. 130–130. 1 indexed citations

Strangfeld, Anja, Adrian Richter, Yvette Meißner, et al.. (2014). OP0166 High Risk of Developing Fatal Infections in RA Patients with Congestive Heart Failure. Annals of the Rheumatic Diseases. 73. 124–125. 1 indexed citations

Specker, Christof, Jörg Kaufmann, M. Bohl-Bühler, et al.. (2012). AB0520 Tocilizumab in rheumatoid arthritis – one year interim analysis of the non-interventional ichiban study. Annals of the Rheumatic Diseases. 71. 667–667. 3 indexed citations

Burmester, Gerd R, Ulf Müller‐Ladner, H. Nüßlein, et al.. (2012). AB0467 Rapid achievement of remission with certolizumab pegol was maintained for one year: interim results from fast, a german non-interventional study in rheumatoid arthritis real life patients. Annals of the Rheumatic Diseases. 71. 664–664. 5 indexed citations

10.

Strangfeld, Anja, Maria Eveslage, Matthias Schneider, et al.. (2011). Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?. Annals of the Rheumatic Diseases. 70(11). 1914–1920. 254 indexed citations

11.

Sieper, Joachim, T. Klopsch, Michael Richter, et al.. (2007). Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Annals of the Rheumatic Diseases. 67(3). 323–329. 103 indexed citations

12.

Listing, Joachim, Anja Strangfeld, Rolf Rau, et al.. (2006). Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low – results from RABBIT, the German biologics register. Arthritis Research & Therapy. 8(3). R66–R66. 141 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact